image

The best stocks to buy since 1993

Latest issue now available

SIGN UP NOW
Updates and Ideas

Amryt Pharma - NASDAQ listing expected in 2020

February 2020

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • AMYT
  • Price:
  • 124.5p
Rarely do I want to own, let alone write up, biotech stocks, so when I met Dr Joe Wiley of Dublin-based Amryt Pharma (AMYT; 124.5p) towards the end of last year, it was very much an exception for me. As I describe below, as recently as three months ago Amryt had just one commercial drug and one other in phase III trials. Brokers were looking for sales to be US$21m in 2019 but in September the company concluded a transformational acquisition when it bought two commercial orphan drugs and revenues on a proforma basis are closer to US$150m, with the expectation building that they could climb to US$165-US$168m in the current year. With the US being the bulk of its sales and many of its shareholders there, the company is expe ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe

SUBSCRIBE NOW